Basic Mechanisms of Hemostasis

Kristin M. Seré; Tilman M. Hackeng

doi:10.1055/s-2003-38328

Seminars in Vascular Medicine, Table of Contents

Semin Vasc Med 2003; 03(1): 003-012
DOI: 10.1055/s-2003-38328

Basic Mechanisms of Hemostasis

Kristin M. Seré, Tilman M. Hackeng

Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, Maastricht, The Netherlands

Abstract

ABSTRACT

Hemostasis governs two essential processes of human life in that it maintains the fluidity of blood under physiological conditions and prevents excessive blood loss after injury. Hemostasis is regulated by components of the vessel wall and blood cells and by humoral coagulation factors. Under normal conditions, these components are involved in an active equilibrium through activation, propagation, and termination of the hemostatic pathways. This equilibrium is disturbed upon vascular injury, leading to a procoagulant response when needed. Unfortunately, pathological disturbances can occur as a result of inherited or acquired coagulation factor deficiencies that may lead to bleeding or thrombotic disorders.

KEYWORDS

Blood coagulation - natural anticoagulants - fibrinolysis - thrombosis

Full Text

References

REFERENCES

1 Clemetson K J, Clemetson J M. Platelet collagen receptors. Thromb Haemost . 2001; 86 189-197
2 Lopez J A, Chung D W, Fujikawa K. et al . The alpha and beta chains of human platelet glycoprotein Ib are both transmembrane proteins containing a leucine-rich amino acid sequence. Proc Natl Acad Sci U S A . 1988; 85 2135-2139
3 Nieswandt B, Brakebusch C, Bergmeier W. et al . Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J . 2001; 20 2120-2130
4 Ruggeri Z M. Structure and function of von Willebrand factor. Thromb Haemost . 1999; 82 576-584
5 Sakariassen K S, Bolhuis P A, Sixma J J. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to the subendothelium. Nature . 1979; 279 636-638
6 Nurden A T, Caen J P. Specific roles for platelet surface glycoproteins in platelet function. Nature . 1975; 255 720-722
7 Huizinga E G, Tsuji S, Romijn R A. et al . Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science . 2002; 297 1176-1179
8 Sims P J, Ginsberg M H, Plow E F, Shattil S J. Effect of platelet activation on the conformation of the plasma membrane glycoprotein IIb-IIIa complex. J Biol Chem . 1991; 266 7345-7352
9 Heemskerk J W, Bevers E M, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost . 2002; 88 186-193
10 MacFarlane R G. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature . 1964; 202 498-499
11 Davie E W, Ratnoff O D. Waterfall sequence for intrinsic blood clotting. Science . 1964; 145 1310-1312
12 Morrissey J H, Macik B G, Neuenschwander P F, Comp P C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood . 1993; 81 734-744
13 Gailani D, Broze Jr J G. Factor XI activation in a revised model of blood coagulation. Science . 1991; 253 909-912
14 Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem . 1991; 266 7353-7358
15 von dem Borne A P, Koppelman S J, Bouma B N, Meijers J C. Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen. Thromb Haemost . 1994; 72 397-402
16 Osterud B, Rapaport S I. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A . 1977; 74 5260-5264
17 Broze Jr J G. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med . 1995; 46 103-112
18 Bajzar L, Manuel R, Nesheim M E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem . 1995; 270 14477-14484
19 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem . 1996; 271 16603-16608
20 Bouma B N, Marx P F, Mosnier L O, Meijers J C. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res . 2001; 101 329-354
21 Lorand L, Konishi K. Activation of the fibrin stabilizing factor of plasma by thrombin. Arch Biochem Biophys . 1964; 105 58
22 Ichinose A. Physiopathology and regulation of factor XIII. Thromb Haemost . 2001; 86 57-65
23 Rosenberg R D, Damus P S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem . 1973; 248 6490-6505
24 Bjork I, Olson S T. Antithrombin. A bloody important serpin. Adv Exp Med Biol . 1997; 425 17-33
25 Tollefsen D M, Majerus D W, Blank M K. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem . 1982; 257 2162-2169
26 Tollefsen D M. Heparin cofactor II. Adv Exp Med Biol . 1997; 425 35-44
27 Scott C F, Schapira M, James H L, Cohen A B, Colman R W. Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen. J Clin Invest . 1982; 69 844-852
28 Pizzo S V, Wu S W. Alpha-macroglobulins and kunins. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Haemostasis and Thrombosis, 4th ed Philadelphia: Lippincott, Williams & Williams 2001: 367-379
29 Marcum J A, Atha D H, Fritze L M. et al . Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem . 1986; 261 7507-7517
30 Broze Jr J G. Tissue factor pathway inhibitor. Thromb Haemost . 1995; 74 90-93
31 Girard T J, Warren L A, Novotny W F. et al . Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature . 1989; 338 518-520
32 Novotny W F, Brown S G, Miletich J P, Rader D J, Broze Jr J G. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood . 1991; 78 387-393
33 Novotny W F, Palmier M, Wun T C, Broze Jr J G, Miletich J P. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood . 1991; 78 394-400
34 Valentin S, Larnkjer A, Ostergaard P, Nielsen J I, Nordfang O. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res . 1994; 75 173-183
35 Esmon C. The protein C pathway. Crit Care Med . 2000; 28 S44-S48
36 Esmon C T, Owen W G. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A . 1981; 78 2249-2252
37 Ye J, Rezaie A R, Esmon C T. Glycosaminoglycan contributions to both protein C activation and thrombin inhibition involve a common arginine-rich site in thrombin that includes residues arginine 93, 97, and 101. J Biol Chem . 1994; 269 17965-17970
38 Tsiang M, Lentz S R, Sadler J E. Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. J Biol Chem . 1992; 267 6164-6170
39 Stearns D J, Kurosawa S, Esmon C T. Microthrombomodulin. Residues 310-486 from the epidermal growth factor precursor homology domain of thrombomodulin will accelerate protein C activation. J Biol Chem . 1989; 264 3352-3356
40 Suzuki K, Hayashi T, Nishioka J. et al . A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation. J Biol Chem . 1989; 264 4872-4876
41 Esmon N L, Owen W G, Esmon C T. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem . 1982; 257 859-864
42 Esmon C T, Esmon N L, Harris K W. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem . 1982; 257 7944-7947
43 Rezaie A R, He X, Esmon C T. Thrombomodulin increases the rate of thrombin inhibition by BPTI. Biochemistry . 1998; 37 693-699
44 Rezaie A R, Cooper S T, Church F C, Esmon C T. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem . 1995; 270 25336-25339
45 Okajima K, Koga S, Kaji M. et al . Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost . 1990; 63 48-53
46 Hackeng T M, Tans G, Koppelman S J. et al . Protein C activation on endothelial cells by prothrombin activation products generated in situ: meizothrombin is a better protein C activator than alpha-thrombin. Biochem J . 1996; 319(Pt 2) 399-405
47 Cote H C, Bajzar L, Stevens W K. et al . Functional characterization of recombinant human meizothrombin and meizothrombin(desF1). Thrombomodulin-dependent activation of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI), platelet aggregation, antithrombin-III inhibition. J Biol Chem . 1997; 272 6194-6200
48 Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. J Biol Chem . 1983; 258 163-168
49 Elisen M G, von dem Borne A P, Bouma B N, Meijers J C. Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma. Blood . 1998; 91 1542-1547
50 Fukudome K, Esmon C T. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem . 1994; 269 26486-26491
51 Stearns-Kurosawa D J, Kurosawa S, Mollica J S, Ferrell G L, Esmon C T. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci U S A . 1996; 93 10212-10216
52 Laszik Z, Mitro A, Taylor Jr B F, Ferrell G, Esmon C T. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation . 1997; 96 3633-3640
53 Riewald M, Petrovan R J, Donner A, Mueller B M, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science . 2002; 296 1880-1882
54 Joyce D E, Gelbert L, Ciaccia A, DeHoff B, Grinnell B W. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem . 2001; 276 11199-11203
55 Kisiel W, Canfield W M, Ericsson L H, Davie E W. Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry . 1977; 16 5824-5831
56 Marlar R A, Kleiss A J, Griffin J H. Human protein C: inactivation of factors V and VIII in plasma by the activated molecule. Ann N Y Acad Sci . 1981; 370 303-310
57 Walker F J. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem . 1981; 256 11128-11131
58 Nicolaes G A, Tans G, Thomassen M C. et al . Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem . 1995; 270 21158-21166
59 Solymoss S, Tucker M M, Tracy P B. Kinetics of inactivation of membrane-bound factor Va by activated protein C. Protein S modulates factor Xa protection. J Biol Chem . 1988; 263 14884-14890
60 Rosing J, Hoekema L, Nicolaes G A. et al . Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem . 1995; 270 27852-27858
61 Kalafatis M, Bertina R M, Rand M D, Mann K G. Characterization of the molecular defect in factor VR506Q. J Biol Chem . 1995; 270 4053-4057
62 Eaton D, Rodriguez H, Vehar G A. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry . 1986; 25 505-512
63 Fay P J, Smudzin T M, Walker F J. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem . 1991; 266 20139-20145
64 Jesty J. Analysis of the generation and inhibition of factor Xa. Area under generation curves is independent of enzyme generation rate. J Biol Chem . 1990; 265 17539-17544
65 Fay P J, Smudzin T M. Characterization of the interaction between the A2 subunit and A1/A3-C1-C2 dimer in human factor VIIIa. J Biol Chem . 1992; 267 13246-13250
66 Dahlback B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A . 1993; 90 1004-1008
67 Bertina R M, Koeleman B P, Koster T. et al . Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature . 1994; 369 64-67
68 Voorberg J, Roelse J, Koopman R. et al . Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet . 1994; 343 1535-1536
69 Greengard J S, Sun X, Xu X. et al . Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet . 1994; 343 1361-1362
70 Koster T, Rosendaal F R, de Ronde H. et al . Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet . 1993; 342 1503-1506
71 Ridker P M, Hennekens C H, Lindpaintner K. et al . Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med . 1995; 332 912-917
72 Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost . 1999; 82 259-270
73 Lucas M A, Fretto L J, McKee P A. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem . 1983; 258 4249-4256
74 Suenson E, Lutzen O, Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem . 1984; 140 513-522
75 Wiman B, Lijnen H R, Collen D. On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. Biochim Biophys Acta . 1979; 579 142-154
76 Fowkes F G, Lowe G D, Housley E. et al . Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet . 1993; 342 84-86
77 Ridker P M, Hennekens C H, Cerskus A, Stampfer M J. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation . 1994; 90 2236-2240
78 Loza J P, Gurewich V, Johnstone M, Pannell R. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb Haemost . 1994; 71 347-352
79 Higazi A, Cohen R L, Henkin J. et al . Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor. J Biol Chem . 1995; 270 17375-17380
80 Redlitz A, Tan A K, Eaton D L, Plow E F. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest . 1995; 96 2534-2538
81 Sakharov D V, Plow E F, Rijken D C. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem . 1997; 272 14477-14482
82 Loskutoff D J, van Mourik A J, Erickson L A, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci U S A . 1983; 80 2956-2960
83 Pannekoek H, Veerman H, Lambers H. et al . Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J . 1986; 5 2539-2544
84 Thorsen S, Philips M, Selmer J, Lecander I, Astedt B. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. Eur J Biochem . 1988; 175 33-39
85 Stump D C, Thienpont M, Collen D. Purification and characterization of a novel inhibitor of urokinase from human urine. Quantitation and preliminary characterization in plasma. J Biol Chem . 1986; 261 12759-12766
86 Heeb M J, Espana F, Geiger M. et al . Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. J Biol Chem . 1987; 262 15813-15816
87 Hedner U, Ginsburg D, Lusher J M, High K A. Congenital hemorrhagic disorders: new insights into the pathophysiology and treatment of hemophilia. Hematology (Am Soc Hematol Educ Program) . 2000; 241-265
88 Seligsohn U. Factor XI deficiency. Thromb Haemost . 1993; 70 68-71
89 Ginsburg D. Molecular genetics of von Willebrand disease. Thromb Haemost . 1999; 82 585-591
90 Meade T W, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet . 1987; 2 986-988
91 Bergstrand R, Vedin A, Wilhelmsson C. et al . Myocardial infarction among men below age 40. Br Heart J . 1978; 40 783-788
92 Rosendaal F R. Risk factors for venous thrombotic disease. Thromb Haemost . 1999; 82 610-619
93 Lane D A, Grant P J. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood . 2000; 95 1517-1532
94 Svensson P J, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med . 1994; 330 517-522
95 Rees D C, Cox M, Clegg J B. World distribution of factor V Leiden. Lancet . 1995; 346 1133-1134
96 Sing C F, Haviland M B, Templeton A R, Zerba K E, Reilly S L. Biological complexity and strategies for finding DNA variations responsible for inter-individual variation in risk of a common chronic disease, coronary artery disease. Ann Med . 1992; 24 539-547
97 Rosendaal F R. Venous thrombosis: a multicausal disease. Lancet . 1999; 353 1167-1173
98 Nichols W C, Amano K, Cacheris P M. et al . Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood . 1996; 88 1183-1187
99 Lee D H, Walker I R, Teitel J. et al . Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost . 2000; 83 387-391
100 Vandenbroucke J P, Koster T, Briet E. et al . Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet . 1994; 344 1453-1457
101 Farley T M, Meirik O, Chang C L, Marmot M G, Poulter N R. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet . 1995; 346 1582-1588
102 Rosendaal F R, Koster T, Vandenbroucke J P, Reitsma P H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood . 1995; 85 1504-1508
103 Rosing J, Tans G, Nicolaes G A. et al . Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol . 1997; 97 233-238
104 Rosing J, Middeldorp S, Curvers J. et al . Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet . 1999; 354 2036-2040
105 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh . 1965; 13 516-530
106 Griffin J H, Evatt B, Zimmerman T S, Kleiss A J, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest . 1981; 68 1370-1373
107 Schwarz H P, Fischer M, Hopmeier P, Batard M A, Griffin J H. Plasma protein S deficiency in familial thrombotic disease. Blood . 1984; 64 1297-1300
108 Comp P C, Esmon C T. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med . 1984; 311 1525-1528
109 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood . 1996; 88 3698-3703
110 Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost . 1995; 73 151-161
111 Koster T, Blann A D, Briet E, Vandenbroucke J P, Rosendaal F R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet . 1995; 345 152-155
112 den Heijer M, Koster T, Blom H J. et al . Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med . 1996; 334 759-762
113 Ridker P M, Hennekens C H, Selhub J. et al . Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation . 1997; 95 1777-1782
114 D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood . 1997; 90 1-11
115 Anderson Jr A F, Wheeler H B, Goldberg R J. et al . A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med . 1991; 151 933-938
116 Gibss N M. Venous thrombosis of the lower limbs with particular reference to bed rest. Br J Surg . 1957; 45 209-235
117 Cruickshank J M, Gorlin R, Jennett B. Air travel and thrombotic episodes: the economy class syndrome. Lancet . 1988; 2 497-498
118 Giangrande P L. Air travel and thrombosis. Br J Haematol . 2002; 117 509-512
119 Daly E, Vessey M P, Hawkins M M. et al . Risk of venous thromboembolism in users of hormone replacement therapy. Lancet . 1996; 348 977-980
120 Curvers J, Thomassen M C, Rimmer J. et al . Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost . 2002; 88 5-11
121 Fijnheer R, Horbach D A, Donders R C. et al . Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Thromb Haemost . 1996; 76 514-517
122 Bick R L. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost . 1992; 18 353-372
123 Hutten B A, Prins M H, Gent M. et al . Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol . 2000; 18 3078-3083